R&D Credit Documentation Is Getting Stricter: What Form 6765 Changes Mean for 2026

The R&D credit is a critical benefit for life sciences companies and other research-focused organizations. With the ability to cover up to 25% of qualified costs, the credit can significantly ease the tax burden, fuel innovation, and improve cash flow, even for pre-revenue companies. 

Recent changes to Form 6765 now require taxpayers to track qualified research expenses (QREs) at the project level, and with much greater detail. 

As of the 2026 tax year, Section G of the Form will be mandatory; for 2025, it is still optional as the IRS phases it in. 

For some businesses, this will intensify the compliance burden as they can no longer aggregate their claims. However, this could be viewed as an opportunity to establish more robust R&D ops that support multiple diverse strategies. 

Whichever way you play it, the message is clear: documentation must be specific to business components and defensible in an audit. 

Understanding the Context Behind the Changes

Recent years have seen a massive focus on R&D credits, often accompanied by inflated wage allocations and ineligible claims (i.e., those that fail the four-part test).

The IRS, however, is allowing more time for taxpayers and practitioners to provide feedback on the draft instructions for Form 6765, which is used to claim the research credit. 

The change was introduced to shore up the standard, forcing taxpayers to be accountable by connecting expense claims to specific activities. We expect to see more challenges in 2026 and beyond. 

From a practical standpoint, it makes good sense. Auditors are spread thin. Requiring disclosures up front helps to reduce bottlenecks and is generally more efficient. Plus, it helps make reporting more accurate and granular, helping companies mitigate overspending and understand the true cost of their research.

What’s Changing with Form 6765 for 2025?

In the past, the R&D tax credit was often calculated using aggregated wage reporting. This method is no longer defensible, or at least much less so. 

For 2025, we’re still under the status quo. However, starting with the 2026 tax year, taxpayers must identify the business component to which the credit relates, detail research activities by component, report wages by project, and disclose officer wages included in the calculation. 

This change underscores the need to define and document each employee’s relationship to the project. If you can’t link expenses adequately, your company is at risk for further scrutiny. 

Wage classifications must also be clearly delineated between research wages, direct supervision wages, and direct support wages. You must consider not only how employees qualify based on each category, but also how their time was allocated. 

In practice, documentation workflows must adapt and be defensible, as they are almost certain to be investigated, and vague estimates are unlikely to be accepted. You may be required to disclose methodologies and explain how conclusions were deduced. Transparency and good record-keeping, as always, will win the day. 

The Importance of Good Documentation

When documentation is weak, audits will follow. According to the IRS, it is extending the period for feedback on the draft Instructions for Form 6765 and providing more time for compliance with new reporting requirements related to the research credit, so staying informed and prepared can help you take full advantage of your eligible benefits.

The days of reconstructing documentation at year-end are coming to a close. Doing so after the fact will create inconsistencies that will be challenging to defend. Clinging to this mentality will ultimately put you at a disadvantage; now is the time to shift to the new normal.

For startups, this is vital. The R&D credit provides a significant offset, and establishing a defensible system now will serve you well in the years ahead. 

Since the burden now extends beyond the tax department, finance, engineering, science, development, and leadership must be aligned on how business components are defined, how employee time is tracked and allocated to these components, and generally how projects are tracked over the course of the year. 

How to Prepare for Your 2025 Tax Filing

Tax season is upon us. The better prepared you are, the less stressful it will be. Though the biggest changes won’t occur until next year’s filing, getting ahead of the game will serve you well.

Here are a few tips to get you thinking along the right lines. 

• Identify documentation gaps. Look at your current documentation processes through the lens of Form 6765’s new requirements. You are looking to align expenses to specific projects and eliminate any ambiguity around disclosure. All expenses must be defensible and well-documented.

• Clearly define business components. Formalize each project and tracking methodologies. Establish a project list and update it periodically to ensure it is accurate. 

• Tighten up wage allocation methodologies. Accurate time tracking is essential. At the very least, ensure all methods are well-documented, consistent, and adhered to by all stakeholders. 

• Maintain a running technical narrative for each project. Each project should be described in as much detail as possible, including uncertainties, how they were addressed, what worked, what didn’t, and the technological rationale applied. 

• Keep defensibility front and center. This may require bringing in experienced third-party advisors to ensure an unbiased approach. The most important thing is that your studies can withstand high-level scrutiny. Having an expert in your corner is a distinct advantage as it will help to keep you on the right track and correct course when necessary. 

 Working with a Growise expert gives you a distinct advantage in the wake of recent changes to the R&D tax credit. While the credit isn’t going anywhere, the rules around reporting have. The time is now to adjust documentation strategies to ensure claims are paid. 

IRS changes to Form 6765 lean toward greater transparency, higher standards, and more detailed disclosures. Previous methodologies that relied on aggregate estimates and vague narratives are no longer viable, as they will undoubtedly result in greater scrutiny and increased organizational risk. 

Companies that take these changes seriously and wholeheartedly transform their documentation strategy to align with them will benefit most. The R&D credit is still one of the most powerful tax vehicles a life sciences company can tap into. However, the margin for error is disappearing quickly, and the time to act is now. 

Speak with a Growise expert today. Our CPAs bring decades of knowledge and experience working in highly regulated industries. We understand your challenges and have the tax expertise and insight to help you achieve the growth you envision.